Free Trial

Xilio Therapeutics (XLO) Competitors

+0.02 (+2.00%)
(As of 07/12/2024 ET)


Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include G1 Therapeutics (GTHX), I-Mab (IMAB), Telomir Pharmaceuticals (TELO), Galectin Therapeutics (GALT), Adagene (ADAG), Annovis Bio (ANVS), Seres Therapeutics (MCRB), Adlai Nortye (ANL), OptiNose (OPTN), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical preparations" industry.

Xilio Therapeutics vs.

G1 Therapeutics (NASDAQ:GTHX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.

In the previous week, G1 Therapeutics had 6 more articles in the media than Xilio Therapeutics. MarketBeat recorded 9 mentions for G1 Therapeutics and 3 mentions for Xilio Therapeutics. G1 Therapeutics' average media sentiment score of 0.46 beat Xilio Therapeutics' score of 0.43 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
G1 Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Xilio Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

G1 Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.

24.2% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 6.1% of G1 Therapeutics shares are owned by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

G1 Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 25.39%. Given Xilio Therapeutics' higher possible upside, research analysts plainly believe G1 Therapeutics is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
G1 Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
Xilio Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)

G1 Therapeutics has higher revenue and earnings than Xilio Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 Therapeutics$82.51M2.02-$47.97M-$0.62-5.15
Xilio TherapeuticsN/AN/A-$76.40M-$2.57-0.40

Xilio Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -36.40%. Xilio Therapeutics' return on equity of -74.75% beat G1 Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
G1 Therapeutics-36.40% -74.75% -24.25%
Xilio Therapeutics N/A -153.48%-89.26%

G1 Therapeutics received 303 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 66.38% of users gave G1 Therapeutics an outperform vote.

G1 TherapeuticsOutperform Votes
Underperform Votes
Xilio TherapeuticsOutperform Votes
Underperform Votes


G1 Therapeutics beats Xilio Therapeutics on 11 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XLO vs. The Competition

MetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$37.65M$7.22B$5.27B$8.66B
Dividend YieldN/A2.79%2.84%4.09%
P/E Ratio-0.4021.28156.3718.28
Price / SalesN/A486.642,216.95109.08
Price / CashN/A32.5534.2932.05
Price / Book0.765.934.944.48
Net Income-$76.40M$146.83M$110.78M$215.59M
7 Day Performance13.97%10.50%6.14%5.37%
1 Month Performance-2.86%4.69%4.30%3.37%
1 Year Performance-61.65%-0.56%5.53%0.94%

Xilio Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
G1 Therapeutics
3.3825 of 5 stars
3.38 / 5 stars
+31.3%$131.22M$82.51M-4.05100Gap Up
2.8312 of 5 stars
2.83 / 5 stars
-39.0%$129.41M$3.89M0.00228Positive News
Telomir Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
Galectin Therapeutics
1.5331 of 5 stars
1.53 / 5 stars
+43.6%$128.03MN/A-2.7828Analyst Upgrade
News Coverage
Positive News
High Trading Volume
1.6738 of 5 stars
1.67 / 5 stars
+78.1%$124.97M$18.11M0.00174Short Interest ↑
News Coverage
Gap Down
Annovis Bio
2.0256 of 5 stars
2.03 / 5 stars
-10.4%$123.99MN/A-1.936Analyst Forecast
News Coverage
High Trading Volume
Seres Therapeutics
3.9277 of 5 stars
3.93 / 5 stars
-76.7%$122.98M$126.32M-1.35233Analyst Upgrade
Gap Up
Adlai Nortye
2.2095 of 5 stars
2.21 / 5 stars
N/A$121.77MN/A0.00127Short Interest ↓
Positive News
Gap Down
3.994 of 5 stars
3.99 / 5 stars
+29.5%$118.13M$70.99M-3.87132Short Interest ↑
Positive News
Amylyx Pharmaceuticals
3.5146 of 5 stars
3.51 / 5 stars
-90.6%$116.97M$398.00M-1.61384Analyst Forecast
Short Interest ↓
News Coverage

Related Companies and Tools

This page (NASDAQ:XLO) was last updated on 7/13/2024 by Staff

From Our Partners